Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selpercatinib in the treatment of thyroid cancer.

Future oncology (London, England) - 1 Aug 2025

Gauduchon Thibault, Varnier Romain, Cassier Philippe A

Abstract excerpt

Selpercatinib, a highly selective RET inhibitor, represents a major advancement for RET-driven thyroid cancers, including medullary thyroid cancer (MTC) and radioiodine-refractory differentiated thyroid cancer (DTC). Clinical trials, such as LIBRETTO-001 and LIBRETTO-531, demonstrate its superior efficacy, safety, and tolerability compared to the less specific multikinase inhibitors, with overall response rates...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Neuroendocrine
Share to Clinical Trials as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-ret

Share to Pyrazoles

Share to Pyridines

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 40638871
DOI: 10.1080/14796694.2025.2531575
PMCID: PMC12344793

Genes

RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selpercatinib in the treatment of thyroid cancer.PMID 40638871Read ↗

RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.Semantic proximity Read ↗

Efficacy of Selpercatinib in RET-Altered Thyroid Cancers.Semantic proximity Read ↗

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.Semantic proximity Read ↗

Updates on the Management of Thyroid Cancer.Semantic proximity Read ↗

FDA Approval Summary: Selpercatinib for the Treatment of Lung and Thyroid Cancers with RET Gene Mutations or Fusions.Semantic proximity Read ↗

Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve RET -Mutant Medullary Thyroid CancerSemantic proximity Read ↗

Clinical and Translational Challenges in Thyroid Cancer.Semantic proximity Read ↗

Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy.Semantic proximity Read ↗

Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectivesSemantic proximity Read ↗

Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.Semantic proximity Read ↗

Targeted therapy in thyroid cancer: molecular alterations and clinical management.Semantic proximity Read ↗

The Role of the Kinase Inhibitors in Thyroid CancersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.